Skip to content

Sequential saphenous vein coronary bypass grafting: does number of distal anastomoses per a single vein affect graft patency?

Sequential saphenous vein coronary bypass grafting: does number of distal anastomoses per a single vein affect graft patency?

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RRC-17013170
Enrollment
Unknown
Registered
2017-10-30
Start date
2017-11-01
Completion date
Unknown
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

Two cohorts:Patients who received three distal anastomoses per a single SV conduit versus patients who received two distal anastomoses per a single SV conduit

Sponsors

Zhongshan Hospital Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Consecutive patients with double-vessel or triple-vessel disease who received first-time, isolated off-pump CABG in our medical center from January 2010 to December 2014 were identified. Only patients who received separate grafting of an in-situ left internal mammary artery to the left anterior descending artery and sequential grafting of a single SV to the other coronary territories were included in this study. ;Inclusion criteria: Consecutive patients with double-vessel or triple-vessel disease who received first-time, isolated off-pump CABG in our medical center from January 2010 to December 2014 were identified. Only patients who received separate grafting of an in-situ left internal mammary artery to the left anterior descending artery and sequential grafting of a single SV to the other coronary territories were included in this study. ;Inclusion criteria: Consecutive patients with double-vessel or triple-vessel disease who received first-time, isolated off-pump CABG in our medical center from January 2010 to December 2014 were identified. Only patients who received separate grafting of an in-situ left internal mammary artery to the left anterior descending artery and sequential grafting of a single SV to the other coronary territories were included in this study. ;Inclusion criteria: Consecutive patients with double-vessel or triple-vessel disease who received first-time, isolated off-pump CABG in our medical center from January 2010 to December 2014 were identified. Only patients who received separate grafting of an in-situ left internal mammary artery to the left anterior descending artery and sequential grafting of a single SV to the other coronary territories were included in this study. ;Inclusion criteria: Consecutive patients with double-vessel or triple-vessel disease who received first-time, isolated off-pump CABG in our medical center from January 2010 to December 2014 were identified. Only patients who received separate grafting of an in-situ left internal mammary artery to the left anterior descending artery and sequential grafting of a single SV to the other coronary territories were included in this study.

Exclusion criteria

Exclusion criteria: Cases done with multiple arterial grafts or with more than one SV conduit grafting or with only one distal anastomosis per a SV conduit were excluded to minimize surgical variability. Octogenarians and patients with concomitant malignant tumor were excluded due to limited anticipated life expectancy. In addition, patients with hyperthyroidism, iodine contrast medium allergy, atrial fibrillation, and renal insufficiency may not be suitable candidates for non-invasive coronary computed tomographic (CT) angiography examination, and thus were not involved in the final analysis.;Exclusion criteria: Cases done with multiple arterial grafts or with more than one SV conduit grafting or with only one distal anastomosis per a SV conduit were excluded to minimize surgical variability. Octogenarians and patients with concomitant malignant tumor were excluded due to limited anticipated life expectancy. In addition, patients with hyperthyroidism, iodine contrast medium allergy, atrial fibrillation, and renal insufficiency may not be suitable candidates for non-invasive coronary computed tomographic (CT) angiography examination, and thus were not involved in the final analysis.;Exclusion criteria: Cases done with multiple arterial grafts or with more than one SV conduit grafting or with only one distal anastomosis per a SV conduit were excluded to minimize surgical variability. Octogenarians and patients with concomitant malignant tumor were excluded due to limited anticipated life expectancy. In addition, patients with hyperthyroidism, iodine contrast medium allergy, atrial fibrillation, and renal insufficiency may not be suitable candidates for non-invasive coronary computed tomographic (CT) angiography examination, and thus were not involved in the final analysis.;Exclusion criteria: Cases done with multiple arterial grafts or with more than one SV conduit grafting or with only one distal anastomosis per a SV conduit were excluded to minimize surgical variability. Octogenarians and patients with concomitant malignant tumor were excluded due to limited anticipated life expectancy. In addition, patients with hyperthyroidism, iodine contrast medium allergy, atrial fibrillation, and renal insufficiency may not be suitable candidates for non-invasive coronary computed tomographic (CT) angiography examination, and thus were not involved in the final analysis.;Exclusion criteria: Cases done with multiple arterial grafts or with more than one SV conduit grafting or with only one distal anastomosis per a SV conduit were excluded to minimize surgical variability. Octogenarians and patients with concomitant malignant tumor were excluded due to limited anticipated life expectancy. In addition, patients with hyperthyroidism, iodine contrast medium allergy, atrial fibrillation, and renal insufficiency may not be suitable candidates for non-invasive coronary computed tomographic (CT) angiography examination, and thus were not involved in the final analysis.

Design outcomes

Primary

MeasureTime frame
Sequential SV graft patency;

Secondary

MeasureTime frame
Follow-up clinical outcomes;In-hospital adverse events;

Countries

China

Contacts

Public ContactJi Qiang;Ji Qiang;Ji Qiang;Ji Qiang;Ji Qiang ;;;;

Zhongshan Hospital Fudan University;Zhongshan Hospital Fudan University;Zhongshan Hospital Fudan University;Zhongshan Hospital Fudan University;Zhongshan Hospital Fudan University

ji.qiang@zs-hospital.sh.cn;ji.qiang@zs-hospital.sh.cn;ji.qiang@zs-hospital.sh.cn;ji.qiang@zs-hospital.sh.cn;ji.qiang@zs-hospital.sh.cn+86 15921230800;+86 15921230800;+86 15921230800;+86 15921230800;+86 15921230800

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026